| Talecris Infusion Could Save or Sink Grifols EP Vantage submits:Monday’s announcement that Grifols (GIKLY.PK) will be acquiring Talecris Biotherapeutics (TLCR) shows that size does matter, at least when it comes to blood products. The rationale for the deal appears to be the increasing competition in the blood plasma world, and, as such, the companies that can drive economies of scale should stand a better chance of succeeding. Grifols will be paying $3.2bn for Talecris in a mixture of cash and shares, with the $26.16 per share price tag being made up of $19 in cash and the rest in non-voting shares. Investors, however, reacted negatively to the empire-expanding move, pushing shares in Grifols down by 7% by late afternoon trading to €8.61.Complete Story » seekingalpha.com |
Drug Approval Could Spur IPO Swiss pharmaceutical company Nycomed said the European health regulator approved lung drug Daxas in patients suffering from smoker's lung, a move that could spur the private equity-backed company's IPO plans. online.wsj.com |
Bio-Reference Labs' fiscal 3Q profit jumps 24 pct (AP) Bio-Reference Laboratories Inc. said Thursday its fiscal third-quarter net income jumped 24 percent, as the clinical laboratory testing services provider increased the number of patients served and its revenue per patient. us.rd.yahoo.com |
The Top 10 Nasdaq 100 Stocks to Research Now Dividend Inc. submits: Watch List Summary At the end of the week for September 17, 2010, the top performing stocks from our Nasdaq 100 list for August 15, 2010 are Oracle (ORCL) with a gain of 21.27%, Qualcomm (QCOM) with a gain of 12.07% and Computer Associates (CA) with a gain of 11.57%.Complete Story » seekingalpha.com |
GM IPO Frenzy Fails to Ignite Biotech Offerings The Burrill Report submits: By Michael FitzhughInvestor enthusiasm for the oversubscribed $20 billion General Motors (GM) initial public offering failed to carry over to the biotech sector where a flurry of issues raced to capture some of the excitement sparked by the carmaker’s record offering before the holiday lull. IPOs by Zogenix (ZGNX) and Anacor Pharmaceuticals (ANAC) here, as well as Zealand Pharma in Europe, all debuted to tepid market interest, each pricing well below what company managers hoped to fetch. Complete Story » seekingalpha.com |